Live Updates

7

Nov 2025
WTI Crude Oil declines to $58.90, falling for three consecutive days despite Russian refinery strikes

WTI crude dips below $59 amid rising inventories, weak global manufacturing data, and persistent economic slowdown fears.

7

Nov 2025
Amidst a declining US Dollar, the Japanese Yen strengthens and trades at approximately 153.13

The Yen strengthens on solid Japan data, while USD weakens amid Fed policy reassessment and US uncertainty.

7

Nov 2025
After the BoE’s cautious decision, GBP/USD climbed slightly, trading at 1.3080, still below 1.31

GBP/USD rises slightly post-BoE decision; future moves hinge on inflation data and US economic outlook.

7

Nov 2025
Gold dips under $4,000, losing bullish momentum while monitoring Federal Reserve speakers for guidance

Gold dips below $4,000 amid US shutdown; Fed signals, central bank buying, and data shape outlook.

7

Nov 2025
Natural gas storage change in the United States fell short of forecasts, recording 33B instead of 34B

US gas storage rose 33 bcf, Dow dropped 250 points, gold steady, crypto and forex fluctuated.

7

Nov 2025
The S&P 500 recovered, providing Trading/Stock Signals clients with nearly 70 ES points in gains

S&P 500 rises, Dow falls; gold nears $4,000; Ethereum declines; Fed and legal risks loom.

7

Nov 2025
Daniel Ghali from TDS observes copper’s potential rise as macro and micro factors align

AI-driven capital expenditure and US tariffs are driving copper demand and limiting global copper supply.

7

Nov 2025
Predictions were missed with the Canada Ivey Purchasing Managers Index at 52.4, instead of 55.2

Canada’s PMI drops, US stocks dip, Banxico cuts rates, gold surges, crypto mixed, currencies rebound.

7

Nov 2025
Despite euro area data weakness, the Euro holds steady against the Swiss Franc amidst stable unemployment

Euro rises slightly against Swiss Franc amid weak Eurozone retail sales, balanced ECB outlook, stable Swiss job market.

7

Nov 2025
For Q3, Xeris Biopharma (XERS) announced earnings per share aligned with expectations, improving from last year’s loss

Xeris Biopharma posts break-even EPS, beats revenue estimates; shares up 191% year-to-date despite negative revisions.

Back To Top
server

Hello there 👋

How can I help you?

We're here to help

Chat with us

Start a live conversation through...

  • Telegram
    hold On hold
  • Coming Soon...

Hello there 👋

How can I help you?

telegram

Our Telegram app is currently under maintenance, we apologize for the inconvenience. For immediate assistance, please contact us via our website live support or by email at info@vtmarkets.com.